Liquid Biopsy Market by Technology and Geography - Forecast and Analysis 2022-2026

  • Published: Apr 2022
  • Pages: 119
  • SKU: IRTNTR45000

Enjoy complimentary customisation on priority with our Enterprise License!

Get me the latest version! (includes COVID-19 impact)
Safe and Secure SSL Encrypted

  • Single:

    One user only.
    Quick & easy download option

  • Enterprise:

    Unlimited user access (Within your organization)
    Complimentary Customization Included

2500 USD

The liquid biopsy market share is expected to increase to USD 1.74 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 18.77%.

This liquid biopsy market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. The liquid biopsy market report offers vendor details for AccuraGen Holdings, Adaptive Biotechnologies Corp., ANGLE Plc, Bio Rad Laboratories Inc., Biocept Inc., CellMax Inc., Epigenomics AG, F. Hoffmann La Roche Ltd., GeneFirst Ltd., Guardant Health Inc., HansaBioMed Life Sciences Ltd., Illumina Inc., MDNA Lfe Sciences Inc., MDxHealth Group, NeoGenomics Laboratories Inc., QIAGEN NV, Rarecells Inc., SAGA Diagnostics AB, Siemens Healthcare GmbH, and Thermo Fisher Scientific Inc. among others.

This report further entails liquid biopsy market segmentation, including:

  • Technology - CTC and ctDNA and Exosome and RNA
  • Geography - North America, Europe, Asia, and Rest of World (ROW)

What will the Liquid Biopsy Market Size be During the Forecast Period?

Liquid Biopsy Market Size

Download the Free Report Sample to Unlock the Liquid Biopsy Market Size for the Forecast Period and Other Important Statistics


Liquid Biopsy Market: Key Drivers, Trends, and Challenges

Based on our research output, there has been a positive impact on the market growth during and post-COVID-19 era. The increasing incidence of cancer is notably driving the liquid biopsy market growth, although factors such as limited reimbursement may impede the market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the liquid biopsy industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.

Key Liquid Biopsy Market Driver

One of the key factors driving growth of the liquid biopsy market is the increasing incidence of cancer. Cancer is one of the leading causes of morbidity globally. Globally, the older population is growing rapidly and at a high risk of getting cancer, owing to the rise in average life expectancy. End-users are increasingly preferring liquid biopsy over tissue biopsy as it is non-invasive and can detect the presence of various cancers more effectively using the individual's blood sample. The increasing incidence of cancers will subsequently increase the diagnosis using the liquid biopsy method.

Key Liquid Biopsy Market Trend

The increasing funding/investment for fluid biopsy is a liquid biopsy market trend that is expected to have a positive impact in the coming years. Fluid biopsy gained momentum in the last few years, both as a research tool and as sophisticated diagnostics technology. Hence, the market attracted investors to fund the R&D of new technologies and the development and commercialization of fluid biopsy products. Many vendors, such as GRAIL, Guardant Health, Exosome Diagnostics, Pathway Genomics, and Inivata, received funding from various investors. In May 2019, Blood-based cancer detection firm Thrive Earlier Detection announced its launch, supported by $110 million in funding. The firm also announced plans to commercialize a circulating tumor DNA and protein testing method initially developed at Johns Hopkins University and undergoing validation in a 10,000-person trial with Pennsylvania's Gesinger Health system.

Key Liquid Biopsy Market Challenge

The limited reimbursement will be a major challenge for the liquid biopsy market during the forecast period. Currently, the reimbursement and treatment monitoring for fluid biopsy is limited, and it is performed in a few laboratories. Moreover, reimbursement for fluid biopsy tests in oncology is not guaranteed even after approval, as it is still considered a novel and unproven technique. The reimbursement coverage depends on the type of cancer, early or late screening procedure, and the type of therapy selected. Reimbursement for fluid biopsy is either low in developed countries or not available in a few countries. A fluid biopsy is a new technology in the market, which is highly adopted in developed countries. In developing countries, though there is a high market opportunity, technology is not much adopted. In developing countries such as China and India, a tissue biopsy is mostly preferred over a fluid biopsy. Lack of reimbursement and awareness about fluid biopsy can decline its adoption, which can hinder market growth.

This liquid biopsy market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2022-2026.

Parent Market Analysis

Technavio categorizes the global fluid biopsy market in North America as a part of the global healthcare supplies market that primarily covers manufacturers of medical products, including all categories of supplies such as consumables and disposables like safety needles, syringes, and catheters. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the liquid biopsy market during the forecast period.

Who are the Major Liquid Biopsy Market Vendors?

The report analyzes the market's competitive landscape and offers information on several market vendors, including:


  • AccuraGen Holdings
  • Adaptive Biotechnologies Corp.
  • ANGLE Plc
  • Bio Rad Laboratories Inc.
  • Biocept Inc.
  • CellMax Inc.
  • Epigenomics AG
  • F. Hoffmann La Roche Ltd.
  • GeneFirst Ltd.
  • Guardant Health Inc.
  • HansaBioMed Life Sciences Ltd.
  • Illumina Inc.
  • MDNA Lfe Sciences Inc.
  • MDxHealth Group
  • NeoGenomics Laboratories Inc.
  • Rarecells Inc.
  • SAGA Diagnostics AB
  • Siemens Healthcare GmbH
  • Thermo Fisher Scientific Inc.


This statistical study of the liquid biopsy market encompasses successful business strategies deployed by the key vendors. The liquid biopsy market is fragmented and the vendors are deploying growth strategies such as aiming to differentiate their products based on device quality, the accuracy of results, and associated value-added services to compete in the market.

Product Insights and News

  • Bio Rad Laboratories Inc. - Bio Rad Laboratories Inc. is a public company headquartered in the US. It is a global company generating $2,922.54 million in revenues and has around 7,900 employees. Its revenue from the global fluid biopsy market is a key component of its overall revenues. 
  • Bio Rad Laboratories Inc. - The company offers fluid biopsy such as in the form of fluid which used for the diagnosis and monitoring of disease states, including cancer.

To make the most of the opportunities and recover from the post-COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

The liquid biopsy market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.

Liquid Biopsy Market Value Chain Analysis

Our report provides extensive information on the value chain analysis for the liquid biopsy market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.

Which are the Key Regions for Liquid Biopsy Market?

Liquid Biopsy Market Market segmentation by region

For more insights on the market share of various regions Request for a FREE sample now!

55% of the market's growth will originate from North America during the forecast period. The US and Canada are the key markets for liquid biopsy in North America. Market growth in this region will be slower than the growth of the market in the European and Asian regions.

The increasing number of cancer cases, increasing adoption of technologically advanced biopsy tests, growing older population, high expenditure on the screening of various types of cancers, and the increasing number of biotechnology and pharmaceutical companies pushing demand for anti-cancer drug development will facilitate the liquid biopsy market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.

COVID Impact and Recovery Analysis

The outbreak of COVID-19 had a slight negative impact on the fluid biopsy market in the region. A rise in the number of COVID-19 cases in Q1 2021 led to the imposition of partial lockdowns in several countries, including Canada and Mexico. However, by H2 2020, lockdown restrictions in various countries were lifted to some extent which allowed the movement of people. This led to an increase in the number of people visiting diagnostic centers and hospitals.

What are the Revenue-generating Technology Segments in the Liquid Biopsy Market?

Liquid Biopsy Market Segmentation

To gain further insights on the market contribution of various segments Request for a FREE sample

The liquid biopsy market share growth by the CTC and ctDNA segment will be significant during the forecast period.  ctDNA test is most preferred, as it is highly sensitive and allows analysis of DNA sequence and methylation. Also, it allows timely and dynamic monitoring of tumor progression and can decrease the diagnosis bias from tumor heterogeneity. Vendors are focusing on the development of novel methods for capturing CTCs and ctDNAs to detect a vast array of cancers before the physical manifestation of symptoms and to track the progression of tumors throughout treatment. Companies are also working to explore ctDNA fluid biopsy to detect the emergence of resistant clones, which limits the remission times achieved in patients treated with targeted therapies and to correlate findings from ctDNA with patient outcomes.

This report provides an accurate prediction of the contribution of all the segments to the growth of the liquid biopsy market size and actionable market insights on the post-COVID-19 impact on each segment.


Liquid Biopsy Market Scope

Report Coverage


Page number


Base year


Forecast period


Growth momentum & CAGR

Accelerate at a CAGR of 18.77%

Market growth 2022-2026

$1.74 billion

Market structure


YoY growth (%)


Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 55%

Key consumer countries

US, Canada, Germany, UK, and France

Competitive landscape

Leading companies, Competitive strategies, Consumer engagement scope

Key companies profiled

AccuraGen Holdings, Adaptive Biotechnologies Corp., ANGLE Plc, Bio Rad Laboratories Inc., Biocept Inc., CellMax Inc., Epigenomics AG, F. Hoffmann La Roche Ltd., GeneFirst Ltd., Guardant Health Inc., HansaBioMed Life Sciences Ltd., Illumina Inc., MDNA Lfe Sciences Inc., MDxHealth Group, NeoGenomics Laboratories Inc., QIAGEN NV, Rarecells Inc., SAGA Diagnostics AB, Siemens Healthcare GmbH, and Thermo Fisher Scientific Inc.

Market dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period.

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request for a FREE sample

What are the Key Data Covered in this Liquid Biopsy Market Report?

  • CAGR of the market during the forecast period 2022-2026
  • Detailed information on factors that will drive liquid biopsy market growth during the next five years
  • Precise estimation of the liquid biopsy market size and its contribution to the parent market
  • Accurate predictions on upcoming trends and changes in consumer behavior
  • The growth of the liquid biopsy industry across North America, Europe, Asia, and Rest of World (ROW)
  • A thorough analysis of the market's competitive landscape and detailed information on vendors
  • Comprehensive details of factors that will challenge the growth of liquid biopsy market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch

1 Executive Summary

2 Market Landscape

  • 2.1 Market ecosystem
    • Exhibit 01: Parent market
    • Exhibit 02: Market characteristics
  • 2.2 Value chain analysis
    • Exhibit 03: Value Chain Analysis: Healthcare supplies

3 Market Sizing

  • 3.1 Market definition
    • Exhibit 04: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
    • Exhibit 05: Market segments
  • 3.3 Market size 2020
    • 3.4 Market outlook: Forecast for 2020 - 2025
      • Exhibit 06: Global - Market size and forecast 2020 - 2025 ($ million)
      • Exhibit 07: Global market: Year-over-year growth 2020 - 2025 (%)

    4 Five Forces Analysis

    • 4.1 Five forces summary
      • Exhibit 08: Five forces analysis 2020 & 2025
    • 4.2 Bargaining power of buyers
      • Exhibit 09: Bargaining power of buyers
    • 4.3 Bargaining power of suppliers
      • Exhibit 10: Bargaining power of suppliers
    • 4.4 Threat of new entrants
      • Exhibit 11: Threat of new entrants
    • 4.5 Threat of substitutes
      • Exhibit 12: Threat of substitutes
    • 4.6 Threat of rivalry
      • Exhibit 13: Threat of rivalry
    • 4.7 Market condition
      • Exhibit 14: Market condition - Five forces 2020

    5 Market Segmentation by Technology

    • 5.1 Market segments
      • Exhibit 15: Technology - Market share 2020-2025 (%)
    • 5.2 Comparison by Technology
      • Exhibit 16: Comparison by Technology
    • 5.3 CTC and ctDNA - Market size and forecast 2020-2025
      • Exhibit 17: CTC and ctDNA - Market size and forecast 2020-2025 ($ million)
      • Exhibit 18: CTC and ctDNA - Year-over-year growth 2020-2025 (%)
    • 5.4 Exosome and RNA - Market size and forecast 2020-2025
      • Exhibit 19: Exosome and RNA - Market size and forecast 2020-2025 ($ million)
      • Exhibit 20: Exosome and RNA - Year-over-year growth 2020-2025 (%)
    • 5.5 Market opportunity by Technology
      • Exhibit 21: Market opportunity by Technology

    6 Customer landscape

    7 Geographic Landscape

    • 7.1 Geographic segmentation
      • Exhibit 23: Market share by geography 2020-2025 (%)
    • 7.2 Geographic comparison
      • Exhibit 24: Geographic comparison
    • 7.3 North America - Market size and forecast 2020-2025
      • Exhibit 25: North America - Market size and forecast 2020-2025 ($ million)
      • Exhibit 26: North America - Year-over-year growth 2020-2025 (%)
    • 7.4 Europe - Market size and forecast 2020-2025
      • Exhibit 27: Europe - Market size and forecast 2020-2025 ($ million)
      • Exhibit 28: Europe - Year-over-year growth 2020-2025 (%)
    • 7.5 Asia - Market size and forecast 2020-2025
      • Exhibit 29: Asia - Market size and forecast 2020-2025 ($ million)
      • Exhibit 30: Asia - Year-over-year growth 2020-2025 (%)
    • 7.6 ROW - Market size and forecast 2020-2025
      • Exhibit 31: ROW - Market size and forecast 2020-2025 ($ million)
      • Exhibit 32: ROW - Year-over-year growth 2020-2025 (%)
    • 7.7 Key leading countries
      • Exhibit 33: Key leading countries
    • 7.8 Market opportunity by geography
      • Exhibit 34: Market opportunity by geography ($ million)

    8 Drivers, Challenges, and Trends

    • 8.1 Market drivers
      • 8.2 Market challenges
        • Exhibit 35: Impact of drivers and challenges
      • 8.3 Market trends

        9 Vendor Landscape

        • 9.1 Overview
          • Exhibit 36: Vendor landscape
        • 9.2 Landscape disruption
          • Exhibit 37: Landscape disruption
          • Exhibit 38: Industry risks
        • 9.3 Competitive scenario

          10 Vendor Analysis

          • 10.1 Vendors covered
            • Exhibit 39: Vendors covered
          • 10.2 Market positioning of vendors
            • Exhibit 40: Market positioning of vendors
          • 10.3 ANGLE Plc
            • Exhibit 41: ANGLE Plc - Overview
            • Exhibit 42: ANGLE Plc - Product and service
            • Exhibit 43: ANGLE Plc - Key offerings
          • 10.4 Bio Techne Corp.
            • Exhibit 44: Bio Techne Corp. - Overview
            • Exhibit 45: Bio Techne Corp. - Business segments
            • Exhibit 46: Bio Techne Corp. – Key news
            • Exhibit 47: Bio Techne Corp. - Key offerings
            • Exhibit 48: Bio Techne Corp. - Segment focus
          • 10.5 Biocept Inc.
            • 10.6 CIRCULOGENE
              • Exhibit 53: CIRCULOGENE - Overview
              • Exhibit 54: CIRCULOGENE - Product and service
              • Exhibit 55: CIRCULOGENE - Key offerings
            • 10.7 F. Hoffmann-La Roche Ltd.
              • Exhibit 56: F. Hoffmann-La Roche Ltd. - Overview
              • Exhibit 57: F. Hoffmann-La Roche Ltd. - Business segments
              • Exhibit 58: F. Hoffmann-La Roche Ltd. – Key news
              • Exhibit 59: F. Hoffmann-La Roche Ltd. - Key offerings
              • Exhibit 60: F. Hoffmann-La Roche Ltd. - Segment focus
            • 10.8 Guardant Health Inc.
              • Exhibit 61: Guardant Health Inc. - Overview
              • Exhibit 62: Guardant Health Inc. - Business segments
              • Exhibit 63: Guardant Health Inc. – Key news
              • Exhibit 64: Guardant Health Inc. - Key offerings
            • 10.9 LungLife AI Inc.
              • Exhibit 65: LungLife AI Inc. - Overview
              • Exhibit 66: LungLife AI Inc. - Product and service
              • Exhibit 67: LungLife AI Inc. - Key offerings
            • 10.10 Myriad Genetics Inc.
              • Exhibit 68: Myriad Genetics Inc. - Overview
              • Exhibit 69: Myriad Genetics Inc. - Business segments
              • Exhibit 70: Myriad Genetics Inc. - Key news
              • Exhibit 71: Myriad Genetics Inc. - Key offerings
              • Exhibit 72: Myriad Genetics Inc. - Segment focus
            • 10.11 QIAGEN NV
              • Exhibit 73: QIAGEN NV - Overview
              • Exhibit 74: QIAGEN NV - Business segments
              • Exhibit 75: QIAGEN NV– Key news
              • Exhibit 76: QIAGEN NV - Key offerings
              • Exhibit 77: QIAGEN NV - Segment focus
            • 10.12 SAGA Diagnostics AB
              • Exhibit 78: SAGA Diagnostics AB - Overview
              • Exhibit 79: SAGA Diagnostics AB - Product and service
              • Exhibit 80: SAGA Diagnostics AB – Key news
              • Exhibit 81: SAGA Diagnostics AB - Key offerings

            11 Appendix

            • 11.1 Scope of the report
              • 11.2 Currency conversion rates for US$
                • Exhibit 82: Currency conversion rates for US$
              • 11.3 Research methodology
                • Exhibit 83: Research Methodology
                • Exhibit 84: Validation techniques employed for market sizing
                • Exhibit 85: Information sources
              • 11.4 List of abbreviations
                • Exhibit 86: List of abbreviations

              Research Framework

              Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

              TechnavioINFORMATION SOURCES

              Primary sources

              • Manufacturers and suppliers
              • Channel partners
              • Industry experts
              • Strategic decision makers

              Secondary sources

              • Industry journals and periodicals
              • Government data
              • Financial reports of key industry players
              • Historical data
              • Press releases

              TechnavioDATA ANALYSIS

              Data Synthesis

              • Collation of data
              • Estimation of key figures
              • Analysis of derived insights

              Data Validation

              • Triangulation with data models
              • Reference against proprietary databases
              • Corroboration with industry experts

              TechnavioREPORT WRITING


              • Market drivers
              • Market challenges
              • Market trends
              • Five forces analysis


              • Market size and forecast
              • Market segmentation
              • Geographical insights
              • Competitive landscape
              Interested in this report?
              Get your sample now!
              Liquid Biopsy market growth will increase by $1466.24 million during 2021-2025.
              The liquid biopsy market is expected to grow at a CAGR of 18.73% during 2021-2025.
              Technavio has segmented the liquid biopsy market by technology (CTC and ctDNA and Exosome and RNA) and geographic (North America, Europe, Asia, Rest of World (ROW), North America, Europe, Asia, and ROW).
              ANGLE Plc, Bio Techne Corp., Biocept Inc., CIRCULOGENE, F. Hoffmann-La Roche Ltd., Guardant Health Inc., LungLife AI Inc., Myriad Genetics Inc., QIAGEN NV, SAGA Diagnostics AB are a few of the key vendors in the liquid biopsy market.
              North America will register the highest growth rate of 52.74% among the other regions. Therefore, the liquid biopsy market in North America is expected to garner significant business opportunities for the vendors during the forecast period.
              • US
              • Canada
              • Germany
              • Japan
              • France
              The key factors driving the liquid biopsy market growth are:
              • Increasing incidence of cancer
              • Increasing funding/investment for liquid biopsy
              The liquid biopsy market vendors should focus on grabbing business opportunities from the ctc and ctdna segment as it accounted for the largest market share in the base year.
              • What are the key global market and the regional market share?
              • What are the revenue-generating key market segments?
              • What are the key factors driving and challenging this market’s growth?
              • Who are the key market vendors and their growth strategies?
              • What are the latest trends influencing the growth of this market?
              • What are the variables influencing the market growth in the primary regions?
              • What are the factors influencing the growth of the parent market?
              • Off-the-shelf research reports
              • Reports can be tailored to meet the customer's needs
              • Trusted by more than 100 fortune 500 organizations
              • Information about the market's key drivers, trends, and challenges
              • Parent market analysis
              • Every week, 50,000 people visit our subscription platform
              • Detailed vendors report with competitive landscape
              • Covid-19 impact and recovery analysis
              • Data on revenue-generating market segments
              • Details on the market shares of various regions
              • Five-force market analysis

              Certified ISO 9001 : 2015

              We are ISO recognized

              We are ISO 9001:2015 recognized that ensures quality services and product delivery to our clients.

              We are GDPR and CCPA compliant

              We are GDPR and CCPA compliant! Your transaction & personal information is protected from unauthorized use.

              Safe and Secure SSL Encrypted

              • Single:

                One user only.
                Quick & easy download option

              • Enterprise:

                Unlimited user access (Within your organization)
                Complimentary Customization Included

              2500 USD

              Technavio Get the report (PDF) sent to your email within minutes.

              Subscribe & Save

              Get lifetime access to our
              Technavio Insights

              Customized Report as per your Business Needs

              • Our analysts will work directly with you and understand your needs
              • Get data on specified regions or segments, competitor and Vendors
              • Data will be formatted and presented as per your requirements
              • We offer $1000 worth of FREE customization at the time of purchase

              Let us help you make report more suited to your requirements.

              • Get a competitive breakdown as per your niche industry
              • Customize the data with various metrics that meet your business prerequisite
              • Understand Revenue Sources, Customers and many more
              • Details on Market Share
              • These customizations are done in a short amount of time by our analysts and industry experts
              Enquire Before Buying
              17,000 reports available | Plans starting from just 5,000 USD | Get FREE trial>>